This is a web edition of GBH Daily, a weekday newsletter bringing you local stories you can trust so you can stay informed without feeling overwhelmed.
Today we have a special invitation to join a conversation about healthcare. But first: Cambridge companies Moderna and Merck released a study last week showing that melanoma patients who got nine shots of custom-made mRNA vaccines were about 42% less likely to see their cancer return after two years than those who didn’t.
All 1,100 patients in the study had their high-risk melanomas removed surgically. Then they were randomly assigned to a follow-up treatment: some got an immunotherapy drug called Keytruda that’s already on the market, and some had scientists analyze the genetic markers in their tumors and use mRNA technology to create a vaccine that essentially taught their immune systems to look for and destroy proteins that should only appear if their cancer returned. Side effects were usually minor, with participants reporting sore arms and fatigue, similar to what people might experience after other vaccines.
This treatment is not yet available to patients outside the study, and it’s not clear when the companies will apply for approval to bring it to market. They’re still monitoring study participants to see how the treatment fares over time. It’s also not clear how much it would cost: Tailor-made treatments are usually more expensive. You can read scientists’ thoughts on this study here.
Four Things to Know
1. Open enrollment season: If you’re one of about 350,000 Massachusetts residents who gets health insurance coverage through the Massachusetts Health Connector, listen up: Open enrollment began last week and runs through Jan. 23, 2027, though you must pick a plan by Dec. 23 to have coverage Jan. 1.
With Congress voting not to renew tax breaks that made some plans less expensive, some people might choose plans with lower premiums. But those plans can end up costing more in the long term. “People who are underinsured face a lot of access barriers. They’re much more likely to say they didn’t get care because of the cost. They also are much more prone to medical debt,” said Sara Collins, senior scholar for expanding coverage and access and tracking health system performance at The Commonwealth Fund.
2. Internal affairs finds no wrongdoing in Worcester: Internal affairs investigators with the Worcester Police Department said they don’t believe officers gave City Councilor Kathleen Toomey preferential treatment after she allegedly hit a parked car in September. Officers did not administer a field sobriety test to Toomey.
“While Mrs. Toomey appeared disoriented, which the officers in their interviews attributed to the shock of the crash and the possibility of a medical issue, the officers on scene said they did not observe slurred speech, glassy or bloodshot eyes and did not smell the odor of an alcoholic beverage on her breath,” Captain Sean Murtha wrote in a 53-page report.
3. ‘I can’t afford to live where I work:’ Workers at UMass Amherst, from professors to staff members, had a rally on campus last week to ask for higher pay. They plan to rally again at the State House in Boston in November.
“Some of the workers who are here today have talked about the fact that they have food insecurity. They are using the food bank or the campus food pantry to feed their families,” said Prof. Eve Weinbaum, who teaches sociology and is vice president of the Massachusetts Society of Professors. “Housing prices are unbelievably high in this area, and it’s impossible to afford even a reasonable apartment on a starting salary at UMass.”
4. Bonus ballot question: We are eight days away from the Nov. 3 election. Voters statewide will weigh in on nine statewide ballot measures (and we have in-depth looks at each of them here), but some voters will also see local measures on their ballots.
On the Cape, voters will decide on Question A, which would create a commission with a representative from every town on the Cape. Its members would examine the structure of county government, gather public input and potentially recommend changes. Supporters say it’s a good way to rework the county government’s structure. Opponents say it would give too much power to people already leading local governments. You can hear a discussion of the question here.
Can Massachusetts make history in healthcare again? A debate
By Ian Coss, host of “The Big Dig” and “Mitt & Ted: A Healthcare Story”
Twenty years ago, Massachusetts made history in healthcare, becoming the first state in the nation to even attempt to get all of its residents health insurance. We tell that story in Season 4 of The Big Dig podcast, but I don’t think it’s a spoiler to say that “Romneycare” was not the answer to all our healthcare troubles. The work of fixing American healthcare remains very much unfinished and, in many ways, more urgent than ever.
To spell it out, the cost of healthcare in this country keeps rising, just as government support and subsidies are shrinking. Frustration is mounting, to the point that some young Americans sympathize more with confessed murderer Luigi Mangione than with the health insurance CEO he murdered. Meanwhile, campaigns for the House and Senate around the country have been energized by talk of Medicare for All. It feels as though another window for health reform could be opening, but it’s not clear what that reform will look like.
So, as a follow-up to our series, I wanted to host a debate. The question is: Can Massachusetts once again be a laboratory for the nation? Can we once again make history in healthcare? This time, the question is whether we can go a step further by creating the nation’s first single-payer health system, the kind used in Canada, the United Kingdom and many other countries,where everyone gets health insurance directly from the government.
This idea has received some fresh attention and interest over the past year. So, would single-payer actually work here? Would people like it? Could we afford it? Or is Medicare for All just a nice-sounding slogan that can never become reality? On Nov. 18, we’ll debate these questions. I hope you’ll join us.
Find details and tickets here.